{"id":"W2407327553","doi":"10.1200/jco.2014.32.15_suppl.tps8615","title":"A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Ibrutinib; Medicine; Vincristine; Internal medicine; Oncology; Rituximab; CHOP; Diffuse large B-cell lymphoma; Cyclophosphamide; Lymphoma; Chemotherapy; Chronic lymphocytic leukemia; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.01158287,0.0003980766,0.005795066,0.0007262756,0.00003938156,0.00001821503,0.0003217395,0.000462487,0.00003139204],"category_scores_gemma":[0.004198484,0.0002527615,0.0003311957,0.0005891863,0.0006166676,0.0001950925,0.0001283656,0.0009925992,0.000002959157],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001374565,"about_ca_system_score_gemma":0.007232945,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009779822,"about_ca_topic_score_gemma":0.002090629,"domain_scores_codex":[0.9907767,0.002223873,0.004714295,0.0005102861,0.001160798,0.0006140799],"domain_scores_gemma":[0.981972,0.01238439,0.003772645,0.0004505396,0.0009438744,0.0004765012],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.790257,0.1558627,0.04811826,0.0002922869,0.0003459887,0.001838599,0.0008543108,0.00002967568,0.0001038536,0.00002345647,0.00005666503,0.002217182],"study_design_scores_gemma":[0.9294102,0.05287841,0.008100301,0.0005002339,0.0008140642,0.0003392758,0.0006440511,0.006595395,0.0003913742,0.00002698966,0.00009491786,0.0002047884],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937062,0.0004350586,0.0001987516,0.0003245122,0.0001934351,0.004042871,0.000005488245,0.000008842864,0.001084904],"genre_scores_gemma":[0.9980373,0.0004516559,0.000888269,0.0001701972,0.0001645021,0.00009917517,0.000007848491,0.00005024295,0.0001308077],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1391532,"threshold_uncertainty_score":0.9999925,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03691613082768837,"score_gpt":0.3859590774920135,"score_spread":0.3490429466643252,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}